Table 4.
Outcomes of catheter ablation of atrial fibrillation in the HCM and control groups
| Study | HCM group | Control group | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Follow-up duration (months) |
Atrial arrhythmia recurrence (n, %) |
Absence of atrial arrhythmia at 1 year (n, %) |
Anti-arrhythmic drug (n, %) |
Redo ablation (n, %) |
Follow-up duration (months) |
Arial arrhythmia recurrence (n, %) |
Absence of atrial arrhythmia at 1 year (n, %) |
Anti-arrhythmic drug (n, %) |
Redo ablation (n, %) |
|
| Gaita (2007)11 | 19 ± 10 | 11/25 (44%) |
5/25 (20%) |
16 ± 8 (secondary) 20 ± 4 (idiopathic AF) |
15/52 (28.8%) |
12/52 (23%) |
||||
| McCready (2011)12 | 13 ± 8.9a | 13/14 (92.9%) |
13 ± 8.9a | 104/177 (58.8%) |
||||||
| Hayashi (2011)13 | 29 ± 17 | 8/17 (47%) |
10/17 (58.8%) |
8/17 (47%) |
8/17 (47%) |
24 ± 12 | 15/34 (44%) |
19/34 (55.9%) |
4/34 (12%) |
12/34 (35%) |
| Müssigbrodt (2014)14 | 13/22 (59%) |
6/22 (27.3%) |
5/22 (23%) |
11/22 (50%) |
0 (0%) | 3/22 (14%) |
||||
| Contreras-Valdes (2015)15 | 22 to 67 | 26/40 (65%) |
17/40 (42.5%) |
18/40 (45%) |
13/40 (32.5%) |
35 to 67 | 20/64 (31.3%) |
45/64 (70.3%) |
12/64 (18.8%) |
12/64 (18.8%) |
| Roh (2016)16 | 45 ± 31 (apical HCM) 58 ± 39 (septal HCM) |
16/31 (51.6%) |
8/31 (25.8%) |
54 ± 34 | 24/90 (26.7%) |
9/90 (10%) |
||||
| Ikenaga (2017)17 | 18.8 ± 8.4a | 2/15 (13.3%) |
18.8 ± 8.4a | 8/106 (7.6%) |
||||||
| Chen (2018)18 | 44.3 ± 29.6a | 60/97 (61.9%) |
69/97 (71%) |
44.3 ± 29.6a | 48/97 (49.5%) |
63/97 (64.9%) |
||||
Empty cells indicate that the respective data were not reported in the specific study.
HCM, hypertrophic cardiomyopathy.
a
Follow-up durations pertain to the overall population in these studies.